Antimicrobal susceptibility of Pseudomonas aeruginosa isolates

Author: Mariam Ubilava
Keywords: Pseudomonas aeruginosa, CLSI სტანდარტი;
Annotation:

Pseudomonas aeruginosa is the cause of 10-15% of nosocomial infections worldwide. Treatment of P.aeruginosa infections is usually difficult due to easy development of resistance to antibiotics and other antimicrobial agents. Such infections are associated with high mortality rates ranging from 18 to 61%. Pseudomonas aeruginosa is recognized as one of the most important pulmonary pathogens and the predominant cause of morbidity and mortality in Cystic The aim of this project was to study the antibiotic resistance of P.aeruginosa isolates obtained from the clinical material of the Georgian population. Susceptibility to P.aeruginosa isolates ,obtained from different clinical materials of 58 patients, was studied according to the CLSI(Clinical and Laboratory Standards Institute) standard. Sputum, blood, urine and purulent discharge were used as research materials.14 antibiotics were selected for the study, two of which are used in combination with a broad-spectrum beta-lactam inhibitor. 1.Aminoglycosides (Gentamicin, Amikacin, Tobramycin) 2.Quinolones (Ciprofloxacin) 3.Cephalosporines (Ceftazidime, Cefepime) 4.Carbapenems (Meropenem, Imipenem) 5.Polymyxins (Colistin) 6.Monobactams (Aztreonam) 7.Antipseudomonal penicillins (Piperacillin, Ticarcillin) 8.Ticarcillin / Clavulanic Acid and Piperacillin / Tazobactam The results of the study indicated high-grade resistance in patients to Ticarcillin, Ticarcillin / Clavulanic Acid ,Imipenem and Gentamicin. On the contrary, there was a 100% sensitivity towards Colistin . A high-grade sensitivity was indicated to a wide range of antibiotics: amikacin, aztreonam, piperacillin/tazobactam, tobramycin, ciprofloxacin, For ceftazidime, cefepime, piperacillin, meropenem. Since high resistance to Ticarcillin / Clavulanic Acid has been demonstrated we could suggest that established resistance to antibiotics may be enhanced by beta lactamases.